[{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sacubitril-Valsartan","moa":"angiotensin II receptor antagonists; endopeptidase inhibitors","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"University of Maryland, Baltimore \/ Medtronic plc"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Alere Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Sacubitril-Valsartan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Alere Inc","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ Alere Inc"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Sacubitril-Valsartan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Entresto

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Unity Health Toronto

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Sacubitril/Valsartan is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 27, 2019

                          Lead Product(s) : Sacubitril-Valsartan

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Alere Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Maryland, Baltimore

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          University of Maryland, Baltimore

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Entresto is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 12, 2017

                          Lead Product(s) : Sacubitril-Valsartan

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Medtronic Plc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Brigham and Women's Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Brigham and Women's Hospital

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Sacubitril/Valsartan is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure, Systolic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 18, 2017

                          Lead Product(s) : Sacubitril-Valsartan

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank